Corcept Therapeutics Incorporated (CORT) research: valuation against peers, fundamentals over time, risk and news coverage
CORT
Corcept Therapeutics IncorporatedNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBEARISHInsider Distribution Broadens Across Healthcare and Tech as Buying Narrows to Small-Cap Value
A cluster of Form 4 filings shows concentrated executive selling: Merck EVP DeLuca disposed of $5.9 million, Corcept's chief development officer sold $1.8 million, Twilio director Erika Rottenberg sold $881,000, and A10 Networks' general counsel sold $392,435. Avalo Therapeutics saw both its CMO and CSO reduce stakes. Insider buying was materially smaller and concentrated in value names, with Celanese SVP Murray purchasing $98,004 and Biote executive chairman Marc Beer acquiring over $202,000. Cathie Wood's ARK also trimmed $11.6 million from a surging tech position.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.